Clinical Trial Update: Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant [Phase 2]

View source ↗

Summary

A Phase 2 decentralized trial in advanced breast cancer with a PIK3CA mutation evaluated alpelisib in combination with fulvestrant; the study was terminated and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)
• Piqray (alpelisib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-02-20